ARCHIVES

Adding Velcade Increased Overall Survival By 13.3 Months at Five-Year Analysis

This article is from The Cancer Letter archive.

Vol. 34 No. 12 | December 30, 2011

Download PDF Visit The Full Archive

Related Articles

ODAC Rejects Amsacrine NDA, Renews Idarubicin

September 14, 1990

House Subcommittee voted $1.011 Billion For NCU 1981 Fiscal Year Budget In Closed Door Meeting

August 8, 1980

DCT T Consider Reissuing RFA For Surgical Oncology

March 4, 1983

NCI Advisors Approve $100M Set Aside for Physical Sciences-Oncology Centers.

December 12, 2008

Arbuck Leaves NCI to Guide BMS Oncology Pipeline.

September 7, 2001

FDA Approves Rituxan For NHL With CHOP Therapy

February 24, 2006